IOL Chemicals and Pharmaceuticals Limited IOLCP NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.iolcp.com

IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company operates through, Chemical and Pharmaceutical segments. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.

Market & Price

Market Cap

₹3,785.92 Cr

Current Price

₹128.98

High / Low (52W)

₹136.06 / ₹68.15

Beta

0.27

Valuation

Stock P/E

27.50

Industry PE

37.60

Forward P/E

15.92

PEG Ratio

Book Value

₹59.60

Price to Book

2.16

P/S

1.63

EV/EBITDA

13.84

Dividend Yield

0.76%

Profitability & Returns

ROCE

10.49%

ROE

7.90%

ROA

4.75%

Profit Margin

5.93%

Op Margin

11.65%

EPS (Latest Qtr)

₹1.81

EPS (TTM)

₹4.69

Balance Sheet & Liquidity

Debt/Equity

0.08

Quick Ratio

1.17

Current Ratio

1.78

Debt

₹135.42 Cr

Total Assets

₹2,586.95 Cr

Current Assets

₹1,227.63 Cr

Working Capital

₹537.45 Cr

Ownership

Promoter Holding

63.11%

Chg in Prom Hold

FII / Inst Holding

1.29%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹3,721.71 Cr

Total Revenue (TTM)

₹2,319.06 Cr

EBITDA

₹268.97 Cr

Free Cash Flow

₹-3.31 Cr

Operating Cash Flow

₹214.32 Cr

Shares Outstanding

₹29.35 Cr

Gross Margin

35.88%

Payout Ratio

21.32%

Growth (CAGR)

Revenue 5Y

1.75%

Profit 5Y

-0.36%

Revenue (YoY)

17.40%

Earnings (YoY)

69.70%

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -0.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	IOLCP IOL Chemicals and Pharmaceuticals Limited NSEPHARMA	128.98	27.50	₹3,785.92 Cr	0.76%	10.49%	7.90%	1.75%	-0.36%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	523.30 Cr	527.78 Cr	551.69 Cr	567.53 Cr	580.39 Cr	619.45 Cr
Cost of Revenue	-	354.05 Cr	345.79 Cr	364.33 Cr	368.17 Cr	382.44 Cr	372.26 Cr
Gross Profit	-	169.25 Cr	181.99 Cr	187.36 Cr	199.36 Cr	197.95 Cr	247.19 Cr
Operating Expenses	-	141.06 Cr	137.79 Cr	145.09 Cr	162.27 Cr	160.85 Cr	175.01 Cr
Operating Income	-	28.19 Cr	44.20 Cr	42.27 Cr	37.09 Cr	37.10 Cr	72.18 Cr
EBITDA	-	50.94 Cr	67.28 Cr	69.51 Cr	63.96 Cr	51.36 Cr	94.30 Cr
Interest Expense	-	4.46 Cr	4.03 Cr	4.23 Cr	3.48 Cr	3.63 Cr	3.20 Cr
Pretax Income	-	27.80 Cr	44.70 Cr	45.51 Cr	40.49 Cr	27.55 Cr	70.81 Cr
Tax Provision	-	7.27 Cr	13.28 Cr	11.58 Cr	10.52 Cr	6.97 Cr	17.65 Cr
Net Income	-	20.53 Cr	31.42 Cr	33.93 Cr	29.97 Cr	20.58 Cr	53.16 Cr
Diluted EPS	0.65	0.70	1.07	1.16	1.02	0.70	1.81

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	2,201.69 Cr	2,118.96 Cr	2,079.21 Cr	2,319.06 Cr
Cost of Revenue	-	1,576.71 Cr	1,423.10 Cr	1,391.85 Cr	1,487.08 Cr
Gross Profit	-	624.98 Cr	695.86 Cr	687.36 Cr	831.98 Cr
Operating Expenses	-	444.81 Cr	527.93 Cr	557.05 Cr	643.22 Cr
Operating Income	-	180.17 Cr	167.93 Cr	130.31 Cr	188.76 Cr
EBITDA	-	245.50 Cr	255.40 Cr	224.71 Cr	279.14 Cr
Interest Expense	-	10.69 Cr	10.84 Cr	14.76 Cr	14.55 Cr
Pretax Income	-	188.65 Cr	181.65 Cr	137.96 Cr	184.36 Cr
Tax Provision	-	49.51 Cr	47.22 Cr	36.89 Cr	46.72 Cr
Net Income	-	139.14 Cr	134.43 Cr	101.07 Cr	137.64 Cr
Diluted EPS	-	4.74	4.58	3.44	4.69

Compounded Sales Growth

5 Years:	1.75%
1 Year:	17.40%

Compounded Profit Growth

5 Years:	-0.36%
1 Year:	69.70%

Stock Price Performance

1 Year:	+46.16%
6 Months:	+40.69%
3 Months:	+76.23%
1 Month:	+34.87%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	2,022.13 Cr	2,244.40 Cr	2,382.07 Cr	2,586.95 Cr
Current Assets	-	920.39 Cr	1,119.77 Cr	1,151.34 Cr	1,227.63 Cr
Cash & Equivalents	-	1.39 Cr	7.69 Cr	78.17 Cr	65.35 Cr
Inventory	-	325.52 Cr	424.84 Cr	360.62 Cr	371.07 Cr
Receivables	-	505.28 Cr	471.23 Cr	513.69 Cr	603.13 Cr
Total Liabilities	-	514.41 Cr	632.89 Cr	694.41 Cr	788.40 Cr
Current Liabilities	-	456.26 Cr	560.00 Cr	609.91 Cr	690.18 Cr
Long Term Debt	-	0	0	0	0
Total Debt	-	79.81 Cr	32.76 Cr	117.04 Cr	135.42 Cr
Total Equity	-	1,507.72 Cr	1,611.51 Cr	1,687.66 Cr	1,798.55 Cr
Shares Outstanding	-	29.35 Cr	29.35 Cr	29.35 Cr	29.35 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	122.27 Cr	289.78 Cr	178.62 Cr	214.32 Cr
Investing Cash Flow	-	-120.00 Cr	-190.98 Cr	-154.18 Cr	-198.11 Cr
Financing Cash Flow	-	-4.11 Cr	-92.50 Cr	46.04 Cr	-29.03 Cr
Capital Expenditure	-	-211.82 Cr	-274.17 Cr	-213.55 Cr	-172.99 Cr
Free Cash Flow	-	-89.55 Cr	15.61 Cr	-34.93 Cr	41.33 Cr
Net Change in Cash	-	-1.84 Cr	6.30 Cr	70.48 Cr	-12.82 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	28.4%	32.8%	33.1%	35.9%
Operating Margin %	-	8.2%	7.9%	6.3%	8.1%
Net Margin %	-	6.3%	6.3%	4.9%	5.9%
ROE %	-	9.2%	8.3%	6.0%	7.7%
ROCE %	-	11.5%	10.0%	7.4%	10.0%

Shareholding Pattern

Insiders

63.11%

Institutions

1.29%

Public Float

3.50%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IOLCP

No recent headlines available.

IOLCP · Healthcare